Advanced search    

Search: authors:"C. Brun-Buisson"

4 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Estimating the morbidity and mortality associated with infections due to multidrug-resistant bacteria (MDRB), France, 2012

Background A study based on 2007 data estimated that 386,000 infections due to multidrug-resistant bacteria (MDRB) occurred in Europe that year and 25,000 patients died from these infections. Our objective was to estimate the morbidity and mortality associated with these infections in France. Methods The MDRB considered were methicillin-resistant Staphylococcus aureus (MRSA), ...

Workload associated with mrsa control in surgery: a prospective study alongside a controlled clinical trial

Hospitals , B. Braun, Pfizer , Speaker's bureau of: BioMerieux, Pfizer, Conflict with: Scientific Advisory Board, Destiny Pharma , DaVolterra, BioMérieux, S. Malhotra-Kumar: None declared, C. Brun-Buisson

Treatment of Ventilator-Associated Pneumonia with Piperacillin-Tazobactam/Amikacin Versus Ceftazidime/Amikacin: A Multicenter, Randomized Controlled Trial

In a randomized trial conducted in 27 intensive care units, we compared the clinical efficacy and safety of piperacillin-tazobactam (TAZ; 4 g/0.5 g q.i.d.) and of ceftazidime (CAZ; 1 g q.i.d.), both combined with amikacin (7.5 mg/kg b.i.d.), as therapy for ventilator-associated pneumonia (VAP; acquired after ⩾48 hours of mechanical ventilation). VAP was diagnosed with use of ...